XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report)’s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $2.56 and traded as high as $2.79. XTL Biopharmaceuticals shares last traded at $2.6650, with a volume of 5,791 shares traded.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a report on Thursday, April 2nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, XTL Biopharmaceuticals presently has a consensus rating of “Sell”.
Get Our Latest Analysis on XTLB
XTL Biopharmaceuticals Price Performance
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.
Read More
- Five stocks we like better than XTL Biopharmaceuticals
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for XTL Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XTL Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
